Stable patients and patients with advanced disease: consensus definitions to support sustained scale up of antiretroviral therapy

Tropical Medicine and International Health

Volumn 21, Issue 9, 2016, Pages 1124-1130

  Waldrop, Greer ^a   Doherty, Meg ^a   Vitoria, Marco ^a   Ford, Nathan ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

advanced disease; antiretroviral therapy; differentiated care; stable patients

Indexed keywords

ANTIRETROVIRUS AGENT;

CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; DRUG; HEALTH CARE; MENTAL HEALTH; MORBIDITY; MORTALITY; PREGNANCY; PUBLIC HEALTH; VIRUS; WORLD HEALTH ORGANIZATION;

ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; CONSENSUS DEVELOPMENT; HUMAN; MEDICATION COMPLIANCE; PATIENT ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

EID: 84985994788     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12746     Document Type: Article

References (46)

1. UNAIDS. “15 by 15”. A global target achieved. Geneva, 2015.
2. IeDea AD, Althoff K et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 2014: 65: e8–e16.
3. Siedner M, Ng C, Bassett I et al. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis. Clin Infect Dis 2015: 60: 1120–1127.
4. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach (2nd edn), World Health Organization: Geneva, 2016.
5. Shubber Z, Mills E, Nachega J et al. Patient reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. 21st International AIDS Conference (AIDS 2016), Durban, South Africa, July 18–22, 2016. Abstract THPEB074, 2016.
6. Braitstein P, Brinkhof M, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006: 367: 817–824.
7. Duncombe C, Rosenblum S, Hellmann N et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. Trop Med Int Health 2015: 20: 430–447.
8. EACS. European AIDS Clinical Society Guidelines. Version 8.0. Brussels, October 2015, 2015.
9. Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Manage Sci 1963: 9: 458–468.
10. Jorm A Using the Delphi expert consensus method in mental health research. Aust N Z J Psychiatry 2015: 887–897.
11. Via G, Hussain A, Wells M et al. International evidence-based recommendations for focused cardiac ultrasound. J Am Soc Echocardiogr 2014: 27: 683.e1–683.e33.
12. Weir A, Holmich P, Schache A et al. Terminology and definitions on groin pain in athletes: building agreement using a short Delphi method. Br J Sports Med 2015: 49: 825–827.
13. Goodman C. The Delphi technique: a critique. J Adv Nurs 1987: 12: 729–734.
14. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000: 32: 1008–1015.
15. Diamond I, Grant R, Feldman B et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014: 67: 401–409.
16. WHO. WHO Handbook for Guideline Development (2nd edn), World Health Organization: Geneva, 2014.
17. Lanoy E, Mary-Krause M, Tattevin P et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007: 12: 89–96.
18. Antinori A, Coenen T, Costagiola D et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011: 12: 61–64.
19. Geng E, Hunt P, Diero L et al. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc 2011: 14: 46.
20. d'Arminio Monforte A, Cozzi-Lepri A, Girardi E et al. Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome. Antivir Ther 2011; 16: 1103–1112.
21. Montlahuc C, Guiguet M, Abgrall S et al. Impact of late presentation on the risk of death among HIV-infected people in France (2003–2009). J Acquir Immune Defic Syndr 2013: 64: 197–203.
22. Sabin C, Smith C, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS 2004: 18: 2145–2151.
23. Ford N, Shubber Z, Saranchuk P et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin Infect Dis 2013: 57: 1351–1361.
24. Murphy R, Berzins B, Zala C et al. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy. AIDS 2010: 24: 885–890.
25. Anon. Adult Antiretroviral Therapy Guidelines 2014. Southern African HIV Clinicians Society, 2014a. (Available from: http://www.sahivsoc.org) [27 Aug 2015].
26. Anon. Guidelines. European AIDS Clinical Society. Version 7.1. November 2014b. (Available from: http://www.eacsociety.org/files/guidelines-7.1-english.pdf) [27 Aug 2015].
27. Bemelmans M, Baert S, Goemaere E et al. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health 2014: 19: 968–977.
28. Grimsrud A, Sharp J, Kalombo C et al. Implementation of community-based adherence clubs for stable antiretroviral therapy patients in Cape Town, South Africa. J Int AIDS Soc 2015: 18: 19984.
29. MacLeod W, Maskew M, MacPhail A et al. The feasibility of using screening criteria to reduce clinic visits for stable patients on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2013: 62: e82–e86.
30. O'Connor C, Osih R, Jaffer A. Loss to follow-up of stable antiretroviral therapy patients in a decentralized down-referral model of care in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2011: 58: 429–432.
31. Young B, Hart R, Buchacz K et al. HIV viral load monitoring frequency and risk of treatment failure among immunologically stable HIV-infected patients prescribed combination antiretroviral therapy. J Int Assoc Provid AIDS Care 2015: 536–543.
32. Reekie J, Mocroft A, Sambatakou H et al. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS 2008: 22: 2381–2390.
33. Maselle E, Muhanguzi A, Muhumuza S et al. Reducing turnaround time for laboratory test results does not improve retention of stable HIV-infected adults on POV program: experience from Uganda. J Int AIDS Soc 2014: 17(4 Suppl 3): 19607.
34. Gilks C, Crowley S, Ekpini R et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006: 368: 505–510.
35. Ford N, Stinson K, Gale H et al. CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis. J Int AIDS Soc 2015: 18: 20061.
36. Koole O, Tsui S, Wabwire-Mangen F et al. Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia. Trop Med Int Health 2014: 19: 1397–1410.
37. Luque-Fernandez M, Van Cutsem G, Goemaere E et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One 2013: 8: e56088.
38. Dickson N, McAllister S, Sharples K et al. Late presentation of HIV infection among adults in New Zealand: 2005–2010. HIV Med 2012: 13: 182–189.
39. de Olalla P, Manzardo C, Sambeat M et al. Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001–2009. AIDS Res Ther 2011: 8: 22.
40. Jevtovic D, Salemovic D, Ranin J et al. The prognosis of patients with dissociated virological and immunological responses to HAART. Biomed Pharmacother 2010: 64: 692–696.
41. Mocroft A, Lundgren J, Sabin M et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013: 10: e1001510.
42. Wolbers M, Bucher H, Furrer M et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med 2008: 9: 397–405.
43. Zoufaly A, an der Heiden M, Marcus U et al. Late presentation for HIV diagnosis and care in Germany. HIV Med 2012: 13: 172–181.
44. Hyle E, Sax P, Walensky R. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. JAMA Intern Med 2013: 173: 1746–1748.
45. Leon A, Caceres C, Fernandez E et al. A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study. PLoS One 2011: 6: e14515.
46. WHO. Global report on HIV treatment 2013: results, impact and opportunities. WHO report in partnership with UNICEF and UNAIDS, World Health Organization, Geneva, 2013.